Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Larché, D. Wraith (2005)
Peptide-based therapeutic vaccines for allergic and autoimmune diseasesNature Medicine, 11 Suppl 1
S. Anderton, N. Viner, P. Matharu, P. Lowrey, D. Wraith (2002)
Influence of a dominant cryptic epitope on autoimmune T cell toleranceNature Immunology, 3
J. Verhagen, Bronwen Burton, G. Britton, Ella Shepard, S. Anderton, D. Wraith (2013)
Modification of the FoxP3 Transcription Factor Principally Affects Inducible T Regulatory Cells in a Model of Experimental Autoimmune EncephalomyelitisPLoS ONE, 8
M. Ponsford, G. Mazza, J. Coad, M. Campbell, J. Zajicek, D. Wraith (2001)
Differential responses of CD45+ve T‐cell subsets to MBP in multiple sclerosisClinical & Experimental Immunology, 124
L. Santambrogio, A. Sato, F. Fischer, M. Dorf, L. Stern (1999)
Abundant empty class II MHC molecules on the surface of immature dendritic cells.Proceedings of the National Academy of Sciences of the United States of America, 96 26
(2018)
Low avidity recognition of selfantigen by T cells permits escape from central tolerance. Immunity
C Gagliani, CF Magnani, SGM Huber, M Pala, P Licona-Limon, B Guo (2014)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cellsNat Med, 19
Bronwen Burton, G. Britton, Hai Fang, J. Verhagen, B. Smithers, C. Sabatos-Peyton, Laura Carney, J. Gough, S. Strobel, D. Wraith (2014)
Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapyNature Communications, 5
(2009)
inventors; Composition of myelin basic peptide peptides patent WO 2009056833
George Liu, P. Fairchild, Richard Smith, J. Prowle, D. Kioussis, D. Wraith (1995)
Low avidity recognition of self-antigen by T cells permits escape from central tolerance.Immunity, 3 4
K. Garber (2014)
Immunology: A tolerant approachNature, 507
S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda (2011)
Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995.Journal of immunology, 186 7
W. Liao, Jian-Xin Lin, W. Leonard (2011)
IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation.Current opinion in immunology, 23 5
(2014)
A tolerant approach
Ruth Etzensperger, R. McMahon, R. McMahon, E. Jones, Lars Fugger, Lars Fugger (2008)
Dissection of the multiple sclerosis associated DR2 haplotype.Journal of autoimmunity, 31 3
(1995)
Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25)
Graziella Mazza, Ponsford Mary, P. Lowrey, M. Campbell, J. Zajicek, D. Wraith (2002)
Diversity and dynamics of the T‐cell response to MBP in DR2+ve individualsClinical & Experimental Immunology, 128
H. Streeter, R. Rigden, Keith Martin, N. Scolding, D. Wraith (2015)
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MSNeurology® Neuroimmunology & Neuroinflammation, 2
W. Brück (2005)
The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damageJournal of Neurology, 252
C. Constantinescu, N. Farooqi, K. O’Brien, B. Gran (2011)
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 164
Ahmed Badawi, T. Siahaan (2012)
Immune modulating peptides for the treatment and suppression of multiple sclerosis.Clinical immunology, 144 2
L. Madsen, E. Andersson, L. Jansson, M. Krogsgaard, C. Andersen, J. Engberg, J. Strominger, A. Svejgaard, J. Hjorth, R. Holmdahl, K. Wucherpfennig, L. Fugger (1999)
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptorNature Genetics, 23
S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda (1995)
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.Journal of immunology, 155 3
(2016)
ATX-MS-1467 in multiple sclerosis
T. Dellovade, Stefan Rudin, A. Zozulya, B. Tomkinson (2014)
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)Neurology, 82
J. Liu, X. Bai, F. Shi, B. Xiao, H. Li, M. Levi, M. Mustafa, B. Wahren, H. Link (1998)
Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.International immunology, 10 8
B. Metzler, D. Wraith (1993)
Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.International immunology, 5 9
A. Svejgaard (2008)
The immunogenetics of multiple sclerosisImmunogenetics, 60
A. Sundstedt, E. O'Neill, K. Nicolson, D. Wraith (2003)
Role for IL-10 in Suppression Mediated by Peptide-Induced Regulatory T Cells In Vivo 1The Journal of Immunology, 170
(2014)
Erratum: Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells (Nature Medicine (2013) 19 (739-746))
L. Gabryšová, K. Nicolson, H. Streeter, J. Verhagen, C. Sabatos-Peyton, D. Morgan, D. Wraith (2009)
Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10–secreting Th1 cellsThe Journal of Experimental Medicine, 206
(Wraith D, Streeter HB, inventors; Composition of myelin basic peptide peptides patent WO 2009056833 A3. 2009.)
Wraith D, Streeter HB, inventors; Composition of myelin basic peptide peptides patent WO 2009056833 A3. 2009.Wraith D, Streeter HB, inventors; Composition of myelin basic peptide peptides patent WO 2009056833 A3. 2009., Wraith D, Streeter HB, inventors; Composition of myelin basic peptide peptides patent WO 2009056833 A3. 2009.
(2014)
A tolerant approach. Nature
H. Groux, M. Bigler, Jan Devries, M. Roncarolo (1996)
Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cellsThe Journal of Experimental Medicine, 184
C. Oreja-Guevara, Jaime Ramos-Cejudo, L. Aroeira, Beatriz Chamorro, E. Díez-Tejedor (2012)
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or NatalizumabBMC Neurology, 12
(2009)
inventors; Composition of myelin basic peptide peptides patent WO
C. Burkhart, George Liu, S. Anderton, B. Metzler, D. Wraith (1999)
Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10.International immunology, 11 10
Kumar Kuna, Chougule, MJ Elliott, De Coppi, Speggiorin, JJ Hsuan, Lowdell, Mw, Birchall (2013)
Research Highlights and Editors’ PicksTransplantation Journal, 95
(Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol. 1998;28:1251–61. https://doi.org/10.1002/(SICI)1521-4141(199804)28:04<1251:AID-IMMU1251>3.0.CO;2-O.)
Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol. 1998;28:1251–61. https://doi.org/10.1002/(SICI)1521-4141(199804)28:04<1251:AID-IMMU1251>3.0.CO;2-O.Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol. 1998;28:1251–61. https://doi.org/10.1002/(SICI)1521-4141(199804)28:04<1251:AID-IMMU1251>3.0.CO;2-O., Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol. 1998;28:1251–61. https://doi.org/10.1002/(SICI)1521-4141(199804)28:04<1251:AID-IMMU1251>3.0.CO;2-O.
S. Anderton, D. Wraith (1998)
Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelinEuropean Journal of Immunology, 28
A. Gajofatto, M. Calabrese, M. Benedetti, S. Monaco (2013)
Clinical, MRI, and CSF Markers of Disability Progression in Multiple SclerosisDisease markers, 35
(ClinicalTrials.gov. ATX-MS-1467 in multiple sclerosis. https://clinicaltrials.gov/ct2/show/NCT01973491?term=ATX-MS-1467&rank=1. Accessed February 29, 2016.)
ClinicalTrials.gov. ATX-MS-1467 in multiple sclerosis. https://clinicaltrials.gov/ct2/show/NCT01973491?term=ATX-MS-1467&rank=1. Accessed February 29, 2016.ClinicalTrials.gov. ATX-MS-1467 in multiple sclerosis. https://clinicaltrials.gov/ct2/show/NCT01973491?term=ATX-MS-1467&rank=1. Accessed February 29, 2016., ClinicalTrials.gov. ATX-MS-1467 in multiple sclerosis. https://clinicaltrials.gov/ct2/show/NCT01973491?term=ATX-MS-1467&rank=1. Accessed February 29, 2016.
Nuruddeen Lewis, L. Patnaude, Josephine Pelletier, D. Souza, S. Lukas, F. King, Jon Hill, Dimitria Stefanopoulos, Kelli Ryan, S. Desai, D. Skow, S. Kauschke, Andre Broermann, D. Kuzmich, C. Harcken, E. Hickey, Louise Modis, Ralf Linker (2014)
A GPBAR1 (TGR5) Small Molecule Agonist Shows Specific Inhibitory Effects on Myeloid Cell Activation In Vitro and Reduces Experimental Autoimmune Encephalitis (EAE) In VivoPLoS ONE, 9
S. Ramagopalan, G. Ebers (2009)
Multiple sclerosis: major histocompatibility complexity and antigen presentationGenome Medicine, 1
Neurol Ther (2018) 7:103–128 https://doi.org/10.1007/s40120-018-0094-z ORIGINAL RESEARCH ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 3 Ob1)F1 Mice by Induction of IL-10-Secreting iTregs . . . Adriano Luı´s Soares De Souza Stefan Rudin Rui Chang . . . . Keith Mitchell Timothy Crandall Shuning Huang Ji-Kyung Choi . . . Shinji L. Okitsu Danielle L. Graham Blake Tomkinson Tammy Dellovade Received: January 8, 2018 / Published online: March 14, 2018 The Author(s) 2018. This article is an open access publication humanized (DR2 9 Ob1)F1 mouse in a dose- ABSTRACT dependent fashion. Methods and Results: Our study extends these Introduction: Antigen-specific immunotherapy observations to show that subcutaneous treat- could provide a targeted approach for the ment with 100 lg of ATX-MS-1467 after induc- treatment of multiple sclerosis that removes the tion of EAE in the same mouse model reversed need for broad-acting immunomodulatory established clinical disability (p \ 0.0001) and drugs. ATX-MS-1467 is a mixture of four pep- histological markers of inflammation and tides identified as the main immune-dominant demyelination (p \ 0.001) compared with disease-associated T-cell epitopes in myelin vehicle-treated animals; furthermore, in longi- basic protein (MBP), an autoimmune target for tudinal magnetic resonance imaging analyses, activated
Neurology and Therapy – Springer Journals
Published: Mar 14, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.